Vernal keratoconjunctivitis: Current immunological and clinical evidence and the potential role of omalizumab

Vernal keratoconjunctivitis (VKC) is a severe ocular allergic disease characterized by chronic inflammation of the cornea and conjunctiva that may lead to loss of visual acuity and blindness.

The disease occurs primarily in children and is more common in geographical regions characterized by warm temperatures and high humidity.

The clinical manifestations of VKC, when inadequately treated, may lead to severe complications and corneal damage.

The prevalence of allergen sensitization, specific serum immunoglobulin E (IgE), and specific tear IgE was reported in approximately 55%–60% of patients with VKC, confirming the involvement of IgE-mediated and non−IgE-mediated mechanisms in the pathophysiology of the condition.

This article explores current knowledge on the immunological pathways of VKC and the role of the monoclonal anti-IgE antibody, omalizumab, in its management.

The review evaluated the effects of omalizumab beyond the direct IgE-mediated reactions and discusses its potential as a therapeutic target for VKC.

Multiple retrospective analyses, case series, and case reports have reported the effectiveness of omalizumab in the management of VKC.

A summary of the clinical data from these studies revealed that in children with VKC omalizumab treatment was well tolerated with improvement or resolution of ocular symptoms, reduction in steroid use, and enhancement of quality of life.

Omalizumab may serve as a promising treatment option for VKC due to its ability to target both IgE-mediated and non−IgE-mediated pathophysiological pathways.

Larger, controlled clinical trials are needed to support these findings.